NHS Fast Tracks First Targeted Anal Cancer Treatment After Trial Shows 11 Extra Months

MHRA approves retifanlimab for advanced anal cancer, its second UK approval for the drug

The MHRA approved retifanlimab (ZYNYZ) with chemotherapy for inoperable or spread anal canal cancer on 5 November, after a 308-person study.

NHS Fast Tracks First Targeted Anal Cancer Treatment After Trial Shows 11 Extra Months

NHS patients with advanced anal cancer can now receive retifanlimab, which extended average survival by 11 months in trials.

NHS fast tracks rollout of first ever targeted treatment for anal cancer

NHS patients living with advanced anal cancer can now benefit from a new life-extending treatment, hailed by the NHS’s top cancer doctor as “one of the most significant steps in decades” for people with the disease. The NHS rollout follows a major clinical trial which found that patients receiving the treatment lived on average 11 […]

MHRA Approves Retifanlimab for Advanced Anal Cancer Treatment

Adults living with certain forms of advanced anal cancer in the UK now have access to a new treatment option after the Medicines and Healthcare products Regulatory Agency (MHRA) approved…